These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Higher efficacy of intermediate dose cytarabine + G-CSF compared to cyclophosphamide + G-CSF in hematopoietic stem cell mobilization in patients with multiple myeloma. Bogucka-Fedorczuk A; Czyz A; Kalicińska E; Sawicki M; Laszkowska-Lewko M; Wicherska-Pawłowska K; Rybka J; Szeremet A; Prajs I; Szymczak D; Wróbel T J Clin Apher; 2020 Aug; 35(4):246-254. PubMed ID: 32298020 [TBL] [Abstract][Full Text] [Related]
5. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715 [TBL] [Abstract][Full Text] [Related]
6. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF. Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597 [TBL] [Abstract][Full Text] [Related]
7. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
9. Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone. Benyamini N; Avivi I; Dann EJ; Zuckerman T; Lavi N; Katz T Ann Hematol; 2017 Mar; 96(3):461-467. PubMed ID: 28013359 [TBL] [Abstract][Full Text] [Related]
10. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Nazha A; Cook R; Vogl DT; Mangan PA; Gardler M; Hummel K; Cunningham K; Luger SM; Porter DL; Schuster S; O'Doherty U; Siegel D; Stadtmauer EA Bone Marrow Transplant; 2011 Jan; 46(1):59-63. PubMed ID: 20421869 [TBL] [Abstract][Full Text] [Related]
11. Selection of a mobilization regimen for multiple myeloma based on the response to induction therapy: granulocyte-colony stimulating factor (G-CSF) alone versus high-dose cyclophosphamide plus G-CSF. Jang JE; Cheong JW; Kim SJ; Cho H; Suh C; Lee H; Eom HS; Yhim HY; Lee WS; Min CK; Lee JH; Park JS; Kim JS Leuk Lymphoma; 2016; 57(6):1389-97. PubMed ID: 26428939 [TBL] [Abstract][Full Text] [Related]
12. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. Zannetti BA; Saraceni F; Cellini C; Fabbri E; Monaco F; Guarini A; Laszlo D; Martino M; Olivieri A; Imola M; Tosi P; Chiarucci M; Zuffa E; Lanza F Transplant Cell Ther; 2021 Mar; 27(3):244.e1-244.e8. PubMed ID: 33781522 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. Martino M; Recchia AG; Moscato T; Fedele R; Neri S; Gentile M; Alati C; Vincelli ID; Piro E; Penna G; Musolino C; Ronco F; Molica S; Morabito F Cytotherapy; 2015 Oct; 17(10):1485-93. PubMed ID: 26188967 [TBL] [Abstract][Full Text] [Related]
14. Single-dose etoposide is an effective and safe protocol for stem cell mobilization in patients with multiple myeloma. Park Y; Kim DS; Jeon MJ; Lee BH; Yu ES; Kang KW; Lee SR; Sung HJ; Nam MH; Yoon SY; Choi CW; Kang ES; Cho D; Kim K; Kim BS; Kim DW; Kim SJ J Clin Apher; 2019 Oct; 34(5):579-588. PubMed ID: 31283042 [TBL] [Abstract][Full Text] [Related]
15. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
16. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison. Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692 [TBL] [Abstract][Full Text] [Related]
17. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma]. Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691 [TBL] [Abstract][Full Text] [Related]
18. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. Winkelmann N; Desole M; Hilgendorf I; Ernst T; Sayer HG; Kunert C; Mügge LO; Hochhaus A; Scholl S J Cancer Res Clin Oncol; 2016 Dec; 142(12):2603-2610. PubMed ID: 27640002 [TBL] [Abstract][Full Text] [Related]
19. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Mark T; Stern J; Furst JR; Jayabalan D; Zafar F; LaRow A; Pearse RN; Harpel J; Shore T; Schuster MW; Leonard JP; Christos PJ; Coleman M; Niesvizky R Biol Blood Marrow Transplant; 2008 Jul; 14(7):795-8. PubMed ID: 18541199 [TBL] [Abstract][Full Text] [Related]
20. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma. Keklik M; Karakus E; Kaynar L; Akyol G; Guven ZT; Celik S; Baydar M; Sanlı N; Unal A; Cetin M Transfus Apher Sci; 2020 Oct; 59(5):102844. PubMed ID: 32586769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]